摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazole

中文名称
——
中文别名
——
英文名称
3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazole
英文别名
5-(3-cyclopentyloxy-4-methoxyphenyl)-1H-pyrazole
3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazole化学式
CAS
——
化学式
C15H18N2O2
mdl
——
分子量
258.32
InChiKey
ZYHORWCWEHOKKO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    47.1
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazole三乙胺 作用下, 反应 21.0h, 生成 1-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazol-1-yl}-3-morpholin-4-ylpropan-2-ol dihydrochloride
    参考文献:
    名称:
    [EN] NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY
    [FR] NOUVEAUX COMPOSÉS PRÉSENTANT UNE ACTIVITÉ D'INHIBITION SÉLECTIVE VIS-À-VIS DE PDE4D
    摘要:
    化合物的化学式(I),其中Z = 环戊基,环丙甲基,-CH3;R' = -CH3,CHF2,X = 化学式(II)(III)(IV)(V),Y = -CO;-C=O(CH2),-CH(OH)-CH2,-CH2-C=O,-CH2-CH2-C=O;-CH2-CH(OH)-CH2,-CH2-CH(OCOR1)-CH2,NR2 = -N(CH2-CH2OH)2,化学式(VI)(VII)(VIII)(IX)(X)(XI),R1 = 可选择地取代的C1-C8烷基,可选择地取代的芳基;可选择地取代的芳基烷基,优选C1-C3烷基,更优选CH3;以及其对映体,异构体和药学上可接受的盐;这些化合物具有PDE4D抑制活性,可用作治疗痴呆症,特别是阿尔茨海默病,并改善记忆的药物。
    公开号:
    WO2015121212A1
  • 作为产物:
    描述:
    1-乙烯基咪唑3-环戊氧-4-甲氧基苯甲醛对甲苯磺酰肼 、 sodium hydroxide 作用下, 以 乙腈 为溶剂, 反应 49.33h, 以65%的产率得到3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazole
    参考文献:
    名称:
    New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment
    摘要:
    Phosphodiesterase type 4D (PDE4D) has been indicated as a promising target for treating neurodegenerative pathologies such as Alzheimer's Disease (AD). By preventing cAMP hydrolysis, PDE4 inhibitors (PDE4Is) increase the cAMP response element-binding protein (CREB) phosphorylation, synaptic plasticity and long-term memory formation. Pharmacological and behavioral studies on our hit GEBR-7b demonstrated that selective PDE4DIs could improve memory without causing emesis and sedation. The hit development led to new molecule series, herein reported, characterized by a catechol structure bonded to five member heterocycles. Molecular modeling studies highlighted the pivotal role of a polar alkyl chain in conferring selective enzyme interaction. Compound 8a showed PDE4D3 selective inhibition and was able to increase intracellular cAMP levels in neuronal cells, as well as in the hippocampus of freely moving rats. Furthermore, 8a was able to readily cross the blood-brain barrier and enhanced memory performance in mice without causing any emetic-like behavior. These data support the view that PDE4D is an adequate molecular target to restore memory deficits in different neuropathologies, including AD, and also indicate compound 8a as a promising candidate for further preclinical development. (C) 2016 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2016.08.018
点击查看最新优质反应信息

文献信息

  • Phosphodiesterase 4 inhibitors
    申请人:Dunn F. Robert
    公开号:US20070254913A1
    公开(公告)日:2007-11-01
    Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
    选择性PDE4抑制是通过芳基和杂环基吡唑化合物实现的。与罗利普兰(rolipram)等化合物相比,这些化合物表现出更好的PDE4抑制作用,并且在抑制其他类PDE时表现出选择性。
  • [EN] PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS<br/>[FR] DERIVES DU PYRAZOLE INHIBITEURS DE LA PHOSPHODIESTERASE 4
    申请人:MEMORY PHARM CORP
    公开号:WO2004094411A1
    公开(公告)日:2004-11-04
    Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
    通过芳基和杂环芳基吡唑化合物实现选择性PDE4抑制。与罗利普兰等化合物相比,这些化合物表现出更好的PDE4抑制作用,并且在抑制其他类PDEs方面表现出选择性。
  • PHOSPHODIESTERASE 4 INHIBITORS
    申请人:Hopper Allen
    公开号:US20090221661A1
    公开(公告)日:2009-09-03
    Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
    选择性PDE4抑制是由芳基和杂环基吡唑化合物实现的。与如Rolipram等化合物相比,这些化合物表现出更好的PDE4抑制作用,并且在抑制其他类别的PDE方面表现出选择性。
  • New compounds as selective PDE4D inhibitors
    申请人:UNIVERSITA DEGLI STUDI DI GENOVA
    公开号:EP2907806A1
    公开(公告)日:2015-08-19
    Compounds of formula (I), wherein Z = cyclopentyl, cyclopropylmethyl, -CH3; R' = -CH3, CHF2, X= Y = -CO; -C=O(CH2), -CH(OH)-CH2, -CH2-C=O, -CH2-CH2-C=O; -CH2-CH(OH)-CH2, -CH2-CH(OCOR1)-CH2; NR2 = -N(CH2-CH2OH)2, R1 = optionally substituted C1-C8 alkyl, optionally substituted aryl; optionally substituted aralkyl, preferably C1-C3 alkyl, more preferably CH3; and enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof. These compounds have a PDE4D inhibiting activity and can be used as a medicament for treating dementia, in particular Alzheimer disease, and for improving memory.
    式(I)化合物、 其中 Z = 环戊基、环丙基甲基、-CH3; R' = -CH3、CHF2、 X= y = -co;-c=o(ch2),-ch(oh)-ch2,-ch2-c=o,-ch2-ch2-c=o;-ch2-ch(oh)-ch2,-ch2-ch(ocor1)-ch2; NR2 = -N(CH2-CH2OH)2、 R1 = 任选取代的 C1-C8 烷基,任选取代的芳基;任选取代的芳烷基,优选 C1-C3 烷基,更优选 CH3; 及其对映体、非对映异构体和药学上可接受的盐。 这些化合物具有 PDE4D 抑制活性,可用作治疗痴呆症(尤其是阿尔茨海默病)和改善记忆的药物。
  • Compounds having a selective PDE4D inhibiting activity
    申请人:UNIVERSITÂ DEGLI STUDI DI GENOVA
    公开号:US10017480B2
    公开(公告)日:2018-07-10
    Compounds of formula (I), wherein Z=cyclopentyl. cyclopropylmethyl, —CH3; R′═—CH3, CHF2, X=formula (II) (III) (IV) (V) Y=—CO; —C═O(CH2), —CH(OH)—CH2, —CH2—C═O, —CH2—CH2—C═O; —CH2—CH(OH)—CH2, —CH2—CH(OCOR1)—CH2 NR2═ —N(CH2—CH2OH)2, formula (VI) (VII) (VIII) (IX) (X) (XI) R1=optionally substituted C1-C8 alkyl, optionally substituted aryl; optionally substituted aralkyl, preferably C1-C3 alkyl, more preferably CH3; and enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof; these compounds have a PDE4D inhibiting activity and can be used as a medicament for treating dementia, in particular Alzheimer disease, and for improving memory.
    式 (I) 的化合物,其中 Z= 环戊基。环丙基甲基,-CH3;R′═-CH3,CHF2,X=式(II) (III) (IV) (V) Y=-CO;-C═O(CH2),-CH(OH)-CH2,-CH2-C═O,-CH2-CH2-C═O;-CH2-CH(OH)-CH2,-CH2-CH(OCOR1)-CH2 NR2═ -N(CH2-CH2OH)2,式(VI) (VII) (VIII) (IX) (X) (XI) R1=任选取代的 C1-C8 烷基,任选取代的芳基;任选取代的芳烷基,优选 C1-C3 烷基,更优选 CH3;及其对映体、非对映异构体和药学上可接受的盐;这些化合物具有 PDE4D 抑制活性,可用作治疗痴呆症,特别是阿尔茨海默病和改善记忆的药物。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺